ADXSAyala Pharmaceuticals, Inc.

About Ayala Pharmaceuticals, Inc. (ADXS)

Ayala Pharmaceuticals, Inc. (ADXS) is a Biotechnology company headquartered in Monmouth Junction, NJ, United States whose shares trade over-the-counter on the Expert Market tier.

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers. Ayala's approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma (ACC), T-cell Acute Lymphoblastic Leukemia (T-ALL), and Desmoid Tumors.

Products and services

Ayala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare tumors and aggressive cancers.

ADXS key facts

Ticker symbol

ADXS

Market tier

Expert Market

Sector

Healthcare

Industry

Biotechnology

Headquarters

Monmouth Junction, NJ, United States

Country of incorporation

US

Year of incorporation

2002

Employees

21

Estimated market cap

$1.52M (as of Apr 11, 2025)

Shares outstanding

49,300,067

Reporting standard

Dark: Alternative Reporting Standard

Audit status

Audited

Fiscal year end

12/31

Ayala Pharmaceuticals, Inc. leadership

• Kenneth A. Berlin — CEO, Interim CFO
• Igor Gitelman — Other
• Oren Elmaliah — Other
• Justin W. Chairman — Legal Counsel

Explore more: Biotechnology stocks · Healthcare sector · Expert Market stocks · OTC stocks starting with A